PDF herunterladen
Thromb Haemost 1997; 77(01): 127-132
DOI: 10.1055/s-0038-1655919
Coagulation
Schattauer GmbH Stuttgart

Effect of a 15-Minute Infusion of DDAVP on the Pharmacokinetics and Pharmacodynamics of ™REVASC during a Four-Hour Intravenous Infusion in Healthy Male Volunteers

Autoren

  • Dipti M Amin

    1   The Guy's Drug Research Unit (GDRU Ltd), London

  • Timothy G K Mant

    1   The Guy's Drug Research Unit (GDRU Ltd), London

  • Stephen M Walker

    2   The Ciba Pharmaceuticals, Horsham, UK

  • Roger Kerry

    3   The Ciba Phamaceuticais, Basel, Switzerland

  • Peter Lloyd

    2   The Ciba Pharmaceuticals, Horsham, UK

  • Gilbert Lefèvre

    4   The Laboratories Ciba-Geigy, Rueil-Malmaison, France

  • Philippe Close

    3   The Ciba Phamaceuticais, Basel, Switzerland
Weitere Informationen

Publikationsverlauf

Received 18. April 1996

Accepted after revision 03. Oktober 1996

Publikationsdatum:
11. Juli 2018 (online)

 als PDF herunterladen  Lizenzen und Reprints

Summary

Plasma pharmacokinetics, effect on coagulation parameters, and safety and tolerability of an intravenous infusion of ™REVASC before, during and after a DDAVP infusion were investigated.

Twelve healthy volunteers were given an intravenous bolus dose followed by a constant rate four-hour infusion of ™REVASC. Fifteen-minute infusions of 0.9% saline and DDAVP were started two and three hours respectively after the start of the ™REVASC infusion.

Plasma ™REVASC concentrations were not affected by either the saline or DDAVP infusion. ™REVASC infusion produced an increase in APTT which plateaued between 0.5 and 3 hours. After the DDAVP infusion there was a tendency towards a new lower plateau whilst the ™REVASC infusion continued. There were no serious adverse events or bleeding episodes throughout the study.

In conclusion, the co-administration of intravenous DDAVP has no effect on the plasma pharmacokinetics of ™REVASC and partially reverses the ™REVASC-induced increase in APTT. This may represent a role for DDAVP in the partial reversal of anticoagulation induced by ™REVASC.